Page 70 - JCTR-10-1

66 Zhuang et al. | Journal of Clinical and Translational Research 2024; 10(1): 62-71

Figure 3. Nomogram for 1-year, 5-year, and 10-year disease-specific survival (DSS) in patients with primary retroperitoneal myxoid/round cell liposarcoma.

Figure 4. Calibration plots for internal validation of 1-year, 5-year, and 10-year disease-specific survival nomogram.

groups according to their nomogram scores. Figure 5 illustrates cohort focused on retroperitoneal MLPS/RCLPS to date, based
the DSS of the three groups; the median DSS was 7.0 months on five cases from the National Cancer Center Hospital in Tokyo,
(95% CI: 0.0 – 26.4), 25.4 months (95% CI: 2.2 – 101.8), and MLPS/RCLPS accounted for a mere 2.3% of RPS and 3.2% of all
167 months (95% CI: NA), respectively (p <0.001). The usage of sites [2]. In a large cohort study on retroperitoneal liposarcoma,
the nomogram prediction model is as follows. Assume an MLPS the proportion of MLPS/RCLPS was less than 10% [3,23]. In
patient comes for a consultation in the outpatient department, this study, we retrospectively examined prognostic factors and
with the following basic information: a 65-year-old (60 points) reported long-term survival status based on the SEER database.
divorced (50 points) woman with no history of malignant tumors For the first time, we identified age (HR = 1.039, P < 0.001),
(48 points). She is diagnosed without distant metastasis (0 points), marital status (P = 0.029), previous tumor history (HR = 0.257,
but the lesion is inoperable (28 points). Therefore, the total score P = 0.007), and presence of distant metastasis (HR = 2.206,
for this patient is 176 points, placing her in the high-risk group P = 0.04) as risk factors for DSS. Furthermore, we developed a
(>165 points), with a corresponding prediction of less than 30% for DSS prediction model for retroperitoneal MLPS/RCLPS that
5-year DSS. If existing medications are ineffective in controlling accurately forecasts patients’ prognoses. Patients were stratified
the condition, we recommend considering clinical trial enrollment into three groups based on the nomogram scores. Twenty patients
for this patient. (11.6%) in the high-risk group and thirty-four patients (19.8%) in
4. Discussion the intermediate-risk group had a median DSS of only 7.0 (95% CI,
0.0 – 26.4) months and 25.4 months (95% CI, 2.2 – 101.8 months),
Retroperitoneal MLPS/RCLPS represents a rare subset of an respectively. In contrast, the median DSS for patients in the
already rare group of tumors. According to the only reported low-risk group was 167 (95% CI, NA) months. Based on these

DOI: https://doi.org/10.36922/jctr.00113